Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, …
Over the last 12 months, insiders at Cartesian Therapeutics, Inc. have bought $4.49M and sold $0 worth of Cartesian Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cartesian Therapeutics, Inc. have bought $4.49M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SPRINGER TIMOTHY A () — $8.79M. BARABE TIMOTHY C (director) — $190,500.
The last purchase of 80,301 shares for transaction amount of $1.81M was made by SPRINGER TIMOTHY A () on 2024‑10‑04.
2024-10-04 | 80,301 0.4883% | $22.58 | $1.81M | -10.83% | ||||
2024-10-03 | 119,906 0.6423% | $19.89 | $2.38M | -4.12% | ||||
2024-10-02 | 5,514 0.0258% | $17.38 | $95,822 | +22.40% | ||||
2024-08-12 | director | 7,500 0.0353% | $12.70 | $95,250 | +30.59% | |||
2024-08-12 | 8,016 0.0378% | $12.72 | $101,968 | +30.59% |